Brain disease transmitted by tick bites may be treatable

Brain disease transmitted by tick bites may be treatable
Tick-borne encephalitis is a disease just as nasty as it sounds. Once bitten by an infected tick, some people develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease -- brain swelling, memory loss, and cognitive decline. Cases are on the rise in Central Europe and Russia with some 10,000 incidents reported each year. Vaccines can provide protection, but only for a limited time. There is no cure.


Lead author Marianna Agudelo and colleagues in the laboratory of Rockefeller s Michel C. Nussenzweig examined nearly 800 antibodies obtained from individuals who had recovered from TBE or had been vaccinated to prevent infection. The most potent antibodies, designated VH3-48, turned out to be best suited to fend off future infections. They found that VH3-48 neutralized lab-grown varieties of the TBE virus, as well other tick-borne illnesses including the Langat, Louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses.

The researchers also showed that these powerful antibodies are not common; in fact, most of the antibodies produced by humans exposed to TBE virus are of inferior quality, with the coveted VH3-48 antibodies making only occasional appearances. Moreover, vaccinated patients in the study did not manage to develop any VH3-48 antibodies at all. "You d expect the most prevalent antibodies to be the absolute best, but that is not what we found in TBE," Agudelo says. "This may explain how the virus tricks the immune system, misdirecting it into producing inferior antibodies."

The discovery of VH3-48 provides hope for a more effective TBE vaccine. Current vaccines require three doses spaced over two years and only provide about five years of protection before a booster shot is required. Next-generation vaccines built around coaxing the body into producing the rare VH3-48 antibody could be more potent, require fewer booster shots, and also prove protective against a number of tick-borne viruses.

"A vaccine like this would not just be more elegant, but also better focused," says Michel C. Nussenzweig, the Zanvil A. Cohn and Ralph M. Steinman Professor and head of the Laboratory of Molecular Immunology at Rockefeller. "Now that we have the structures of these antibodies, we know what to target in order to design more effective vaccines."

Broadly neutralizing antibodies may also provide the first specific treatment for TBE. Nussenzweig, Agudelo, and colleagues found that mice infected with TBE recover after receiving antibody therapy, although it remains to be seen if this finding will translate to humans.

"The next step is a clinical trial with the antibodies," Nussenzweig says, "perhaps in Europe where there are many cases, to see whether we can ameliorate the symptoms of those suffering from encephalitis."

Materials provided by Rockefeller University . Note: Content may be edited for style and length.

Rockefeller University. "Brain disease transmitted by tick bites may be treatable." ScienceDaily. ScienceDaily, 9 April 2021. .

Rockefeller University. "Brain disease transmitted by tick bites may be treatable." ScienceDaily. (accessed April 10, 2021).



Nov. 7, 2019 — The new vaccine strategy centers on stimulating the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV. These special antibodies are capable of neutralizing many different ...

Dec. 18, 2018 — Researchers have developed a vaccine that is effective in mice against Powassan virus, an emerging tick-borne virus that can cause life-threatening encephalitis in humans. They also show that the ...

Sep. 10, 2018 — Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. ...

Sep. 8, 2016 — During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection. With an eye ...
News Topics :
Scientists at The Wistar Institute have designed and tested the first of its kind synthetic DNA vaccine against Powassan virus POWV , targeting portions of the virus envelope protein. A rapidly reemerging tick borne disease,...
In the first results to emerge from HIV patient trials of a new generation of so called broadly neutralizing antibodies, researchers have found the experimental therapy can dramatically reduce the amount...
In rare cases, people who have been fully vaccinated against COVID and are immune to the virus can nevertheless develop the disease. New findings from The Rockefeller University now suggest...
Marina Caskey, a researcher who is part of a new clinical trial that shows that broadly neutralizing antibodies can suppress HIV for up to four months, far longer than currently...
SARS CoV 2, the virus that causes COVID 19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread...